Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rare Diseases: Growing Understanding Will Unlock Accelerated Approval, FDA Says

Executive Summary

US FDA officials say they need knowledge of the disease to have the confidence to use accelerated approval.

You may also be interested in...



Common Treatment May Be Removed In Alcoholic Hepatitis Trials

Given effect corticosteroids have on patients, US FDA asks whether they can be excluded from use in alcoholic hepatitis clinical trials.

Moscicki's Move From FDA To PhRMA About 'Best' Use Of Leadership Skills

At inconveniently timed NORD conference, the former CDER deputy center director finds himself unable to speak for either FDA or the Pharmaceutical Research and Manufacturers of America.

FDA Orphan Disease Clinical Trial Grants Aim To Reduce Financial Risk

Agency awards $22m to support 15 clinical trials and approximately $10m for six natural history studies in rare diseases. FDA Commissioner Gottlieb highlights the program as a way for the agency to help de-risk clinical development.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS121796

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel